European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment


To develop a European guideline on pharmacologic treatment of Tourette syndrome (TS) the available literature was thoroughly screened and extensively discussed by a working group of the European Society for the Study of Tourette syndrome (ESSTS). Although there are many more studies on pharmacotherapy of TS than on behavioral treatment options, only a limited number of studies meets rigorous quality criteria. Therefore, we have devised a two-stage approach. First, we present the highest level of evidence by reporting the findings of existing Cochrane reviews in this field. Subsequently, we provide the first comprehensive overview of all reports on pharmacological treatment options for TS through a MEDLINE, PubMed, and EMBASE search for all studies that document the effect of pharmacological treatment of TS and other tic disorders between 1970 and November 2010. We present a summary of the current consensus on pharmacological treatment options for TS in Europe to guide the clinician in daily practice. This summary is, however, rather a status quo of a clinically helpful but merely low evidence guideline, mainly driven by expert experience and opinion, since rigorous experimental studies are scarce.

DOI: 10.1007/s00787-011-0163-7

Extracted Key Phrases

3 Figures and Tables

Citations per Year

554 Citations

Semantic Scholar estimates that this publication has 554 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@inproceedings{Rner2011EuropeanCG, title={European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment}, author={Veit R{\"{o}\ssner and Kerstin J. Plessen and Aribert Rothenberger and Andrea G. Ludolph and Renata Rizzo and Liselotte Skov and Gerd Strand and Jeremy S. Stern and Cristiano Termine and Pieter J. Hoekstra}, booktitle={European Child & Adolescent Psychiatry}, year={2011} }